Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of obinutuzumab versus mycophenolate mofetil in childhood-onset idiopathic nephrotic syndrome
CTR20233730Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab, mycophenolate mofetil in Idiopathic nephrotic syndrome (INS), sponsored by Roche. Started Apr 2024; status: active.
02
Drugs
obinutuzumabmycophenolate mofetil
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on CTR20233730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233730.